Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial

Robin M. Norris, Michael W. Rich, Eugene Braunwald

Research output: Contribution to journalLetterpeer-review

5 Scopus citations

Abstract

To the Editor: For many, the important message of the TIMI Phase II trial (March 9 issue)1 is not so much that the use of a conservative strategy after thrombolysis was vindicated, but that acute myocardial infarction could be treated in 3262 patients, approximately two thirds of whom were in a not-low-risk category, with a six-week mortality rate of under 5 percent. It is, however, difficult to interpret the results of the substudy of intravenous beta-blockade, a treatment that had been investigated extensively during the decade before the introduction of thrombolysis2,3 and that experimental evidence had suggested should be more.

Original languageEnglish
Pages (from-to)612
Number of pages1
JournalNew England Journal of Medicine
Volume321
Issue number9
DOIs
StatePublished - Aug 31 1989

Fingerprint

Dive into the research topics of 'Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial'. Together they form a unique fingerprint.

Cite this